Advair Diskus Articles
FDA's new safety controls for LABA-containing drugs will impact prescribing for the treatment of asthma
26 August 2010
German Court revokes GlaxoSmithKline Viani/Advair patent; Company identifies new malaria leads
21 May 2010
SkyePharma takes back NDA for Flutiform from Abbott Labs
8 February 2010
Nycomed reports satisfactory 3rd-quarter 2009 performance, despite generic erosion of pantoprazole sales
13 November 2009
SkyePharma slumps on US delay for Flutiform
2 September 2009
Zacks analysts view AstraZeneca/Forest deal favorably
18 August 2009
SkyePharma files Flutiform NDA with FDA
1 June 2009
SkyePharma submits Flutiform NDA
30 March 2009
Teva's QVAR effective in "real life" study
23 March 2009
Prasco to distribute GSK generics
16 March 2009
Four Novartis drugs and B-MS
9 March 2009
Japan stock market week to Feb 23, 2009
2 March 2009
Mochida seeks OTC switch for Epadel
9 February 2009
FDA divided on safety of Serevent and Foradil ahead of panel meeting
15 December 2008
GSK's asthma drugs not impacted by genetic profiles
24 March 2008
US FDA begins safety review of LABA asthma drugs
10 March 2008
GSK sees 2008 EPS fall; posts 2007 results
18 February 2008
FDA panel recommends warning on salmeterol
10 December 2007
USA's NIH updated asthma treatment guidelines welcomed by industry
10 September 2007
FDA rejects GSK's 500/50 strength Advair Diskus for COPD
13 August 2007
Japan's Chuikyo adds 13 NCEs to NHI list
18 June 2007
Mixed news for high dose Advair from FDA
7 May 2007
GSK's Arixtra and Seretide/Advair approved in Japan
23 April 2007
GSK's Advair Diskus cuts death risk 17.5%
5 March 2007
CHEST 2006: drug combo cuts death risk in COPD; statins slow lung decline in smokers
30 October 2006
Strong data for GSK's Seretide/Advair in COPD
3 April 2006
AstraZeneca welcomes TORCH trial results
3 April 2006
FDA approves GSK's Flovent in children aged four to 11
27 March 2006
Innovata secures L25M Duohaler asthma deal
19 December 2005
Schering-Plough's Nasonex "superior in scent and taste to GSK's Flonase"
12 September 2005
USA
22 August 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GSK's Seretide Evohaler with built-in counter introduced
20 December 2004
Once/day Alvesco vs twice/day fluticasone
13 September 2004
GSK's 2nd-qtr 2004 EPS drops 12%
2 August 2004
FDA set to speed US Rx-OTC switches?
12 July 2004
GSK's Advair OKed for use in children by FDA
3 May 2004
IVAX wins Seretide patent case in the UK
29 March 2004
Second FDA drug imports "blitz" finds 80% come from Canada
9 February 2004
FDA clears GSK's Advair Diskus 250/50
24 November 2003
US DTC ad spend, and response, levels off
20 October 2003
GSK Canadian on-line drug prices rise
7 July 2003
GSK's Seretide Diskus approved for COPD
2 June 2003
S-P, Novartis link up on asthma product
21 April 2003
IVAX seeks approval for generic Flonase
17 March 2003
Stock Commentary - Europe - 2 weeks to Dec 30
6 January 2003
Stock Commentary - Europe
28 January 2002
GSK boosted by US Advair COPD decision
28 January 2002
Global pulmonary drug delivery market forecasts
24 September 2001
GSK claims Advair superior to Singulair
10 September 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Strong earnings growth for Glaxo Wellcome and SmithKline Beecham
1 November 2000
GW wins approval for Flovent Diskus in over-4s
5 October 2000
Dura gets rights to GW's dermatalogy line
3 October 2000
Prednisone better than fluticasone, says study
8 September 2000
Stock Commentary Europe
31 August 2000
GW's asthma drug wins US approval
29 August 2000
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
GW gains first approval for Seretide MDI
20 June 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
GW files for European approval of Seretide MDI
16 December 1999
Japan gives provisional backing to GW's Relenza, Canada OKs Advair
29 November 1999
GW gets FDA panel backing for Advair
25 November 1999
Stock Commentary Europe
25 November 1999
Flovent outperforms Accolate in asthma study
2 November 1999
GW, S-P push steroids for allergic rhinitis
7 July 1999
A&H cuts Flixotide price in UK
6 July 1999
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
